Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Heterozygosis For Cyp21a2 Mutation Considered As 21-hydroxylase Deficiency In Neonatal Screening.
Author: Soardi, Fernanda Caroline
Lemos-Marini, Sofia Helena V
Coeli, Fernanda Borchers
Maturana, Víctor Gonçalves
Silva, Márcia Duarte Barbosa da
Bernardi, Renan Darin
Justo, Giselle Zenker
de-Mello, Maricilda Palandi
Abstract: Steroid 21-hydroxylase deficiency (21-OHD) accounts for more than 90% of congenital adrenal hyperplasia. CAH newborn screening, in general, is based on 17-hydroxyprogesterone dosage (17-OHP), however it is complicated by the fact that healthy preterm infants have high levels of 17-OHP resulting in false positive cases. We report on molecular features of a boy born pre-term (GA = 30 weeks; weight = 1,390 g) with elevated levels of 17-OHP (91.2 nmol/L, normal < 40) upon neonatal screening who was treated as having CAH up to the age of 8 months. He was brought to us for molecular diagnosis. Medication was gradually suspended and serum 17-OHP dosages mantained normal. The p.V281L mutation was found in compound heterozygous status with a group of nucleotide alterations located at the 3' end intron 4 and 5' end exon 5 corresponding to the splice site acceptor region. Molecular studies continued in order to exclude the possibility of a nonclassical 21-OHD form. The group of three nucleotide changes was demonstrated to be a normal variant since they failed to interfere with the normal splicing process upon minigene studies.
Subject: 17-alpha-hydroxyprogesterone
Adrenal Hyperplasia, Congenital
False Positive Reactions
Infant, Newborn
Neonatal Screening
Premature Birth
Steroid 21-hydroxylase
Citation: Arquivos Brasileiros De Endocrinologia E Metabologia. v. 52, n. 8, p. 1388-92, 2008-Nov.
Rights: aberto
Date Issue: 2008
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_19169499.pdf201.37 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.